Check for updates

#### **OPEN ACCESS**

EDITED BY Ahmed El-Sohemy, University of Toronto, Canada

#### REVIEWED BY Han Feng, Tulane University, United States Antonio Giordano, Temple University, United States

\*CORRESPONDENCE Yidan Tang Vidantang@qq.com Weiyi Zhang Zhangweiyi@wchscu.cn Tao Zhu Xutao.zhu@foxmail.com

RECEIVED 07 June 2023 ACCEPTED 27 November 2023 PUBLISHED 21 December 2023

#### CITATION

Tang Y, Xu X, Zhang S, Kong W, Zhang W and Zhu T (2023) Genetic liability for diet-derived circulating antioxidants, oxidative stress, and risk of osteoarthritis: a Mendelian randomization study. *Front. Nutr.* 10:1233086. doi: 10.3389/fnut.2023.1233086

#### COPYRIGHT

© 2023 Tang, Xu, Zhang, Kong, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Genetic liability for diet-derived circulating antioxidants, oxidative stress, and risk of osteoarthritis: a Mendelian randomization study

Yidan Tang<sup>1,2\*</sup>, Xiaolin Xu<sup>1,2</sup>, Shuangyi Zhang<sup>1,2</sup>, Weishuang Kong<sup>3</sup>, Weiyi Zhang<sup>1,2\*</sup> and Tao Zhu<sup>1,2\*</sup>

<sup>1</sup>Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China, <sup>2</sup>Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China, <sup>3</sup>Department of Surgery, Xuanwei Hospital of Traditional Chinese Medicine, Xuanwei, China

**Background:** Although well-documented, the causal relationships between diet-derived circulating antioxidants, oxidative stress, and osteoarthritis (OA) are equivocal. The objective of this study is to employ two-sample Mendelian randomization (MR) to investigate possible causal relationships among dietary-derived circulating antioxidants, oxidative stress damage indicators, and OA risk.

**Methods:** Single-nucleotide polymorphisms for diet-derived circulating antioxidants (ascorbate,  $\beta$ -carotene, lycopene, retinol, and  $\alpha$ -and  $\gamma$ -tocopherol), assessed as absolute levels and metabolites, as well as oxidative stress injury biomarkers (GSH, GPX, CAT, SOD, albumin, and total bilirubin), were retrieved from the published data and were used as genetic instrumental variables. Summary statistics for gene–OA associations were obtained from publicly available and two relatively large-scale GWAS meta-analyses to date. The inverse-variance weighting method was utilized as the primary MR analysis. Moreover, multivariable MR was used to determine if mediators (BMI and smoking) causally mediated any connection. Furthermore, for each exposure, MR analyses were conducted per outcome database and then meta-analyzed.

**Results:** Genetically predicted absolute retinol level was causally associated with hip OA risk [odds ratios (ORs) = 0.40, 95% confidence interval (CI) = 0.24–0.68, FDR-corrected p = 0.042]. Moreover, genetically predicted albumin level was causally associated with total OA risk (OR = 0.80, 95% CI = 0.75–0.86, FDR-corrected p = 2.20E-11), as well as the risk of hip OA (OR = 0.75, 95% CI = 0.68–0.84, FDR-corrected p = 1.38E-06) and knee OA (OR = 0.82, 95% CI = 0.76–0.89, FDR-corrected p = 4.49E-06). In addition, MVMR confirmed that the effect of albumin on hip OA is independent of smoking initiation, alcoholic drinks per week, and moderate-to-vigorous physical activity levels but may be influenced by BMI.

**Conclusion:** Evidence from our study supports a potentially protective effect of high levels of retinol and albumin on OA risk.

#### KEYWORDS

antioxidant, oxidative stress, osteoarthritis, causal effect, Mendelian

# 1 Introduction

Osteoarthritis (OA) is a degenerative disease of the entire joint, most notably the knee, but also the hand and hip (1). OA affects  $\sim$ 500 million people globally, and its incidence is steadily increasing due to an aging population and an obesity pandemic, resulting in a substantial public health and health economic burden (1). However, current disease-modifying treatments for OA are minimally effective (2). Therefore, it is necessary to find effective strategies to prevent OA.

OA pathogenesis is regulated by multiple predisposing factors, including imbalanced matrix metabolism, aberrant inflammatory response, and excessive oxidative stress (3). Overproduction of ROS and activation of oxidative stress in chondrocytes are major contributors to OA pathogenesis (4, 5). Furthermore, antioxidants, which can help eliminate free radicals and minimize and eliminate oxidative damage, have been identified as possible targets for the primary prevention of OA (6, 7). The current state of research on the association between antioxidants and OA yields conflicting results. Several studies and reviews analyze the potential protective effects of nutrients, including vitamins D, E, and C, on cartilage metabolism and the development of OA (8, 9). However, some studies have not reported the protective effects of the preceding antioxidants on OA (10, 11). Observational studies are, however, limited by confounding factors and reverse causation bias that led to inconsistent results.

Furthermore, age, gender, obesity, joint biomechanics, history of joint surgery, and genetic susceptibility were identified as the risk factors (12). In addition, recent studies implicated the importance of antioxidants in OA (6, 13). Furthermore, redox equilibrium is maintained by a sophisticated antioxidant defense system comprised of both enzymatic and non-enzymatic antioxidants. The major antioxidant systems in the cell are enzymatic antioxidants, which include glutathione S-transferase (GST), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX). Glutathione (GSH), albumin, and total bilirubin are common nonenzymatic antioxidants. Several studies have reported that the levels of GSH, GPX, CAT, and SOD, as well as total bilirubin, were associated with the OA risk (14-17). The current state of research on the association between albumin and OA yields conflicting results; as a clinical study reported, the concentration of albumin in osteoarthritic knee-joint effusions was distinctly lower than in sera of healthy adults (18), but higher serum albumin levels in OA patients were described in another study (19). Existing observational studies are unable to rule out the effect of reverse causality or unmeasured confounding factors such as socio-economic status, dietary habits, or other health-related behaviors (11, 20, 21). In addition, intervention trials may have limitations due to the potential for unknown risks and harm to subjects. In addition, intervention trials may be confounded by many uncertainty factors such as time, dose, duration, and onset and progression. Therefore, the causal associations between antioxidant levels and the risk of OA remain unknown.

Mendelian randomization (MR) is a viable approach for determining causation by using genetic variations as instrumental variables (IVs) to investigate the causal influence of exposure on outcome. This approach is based on the notion that genetic variations are assigned at random during conception. It is less susceptible to environmental or lifestyle influences, and it decreases the bias caused by reverse causality or confounding factors. This study used antioxidants (including diet-derived circulating antioxidants and their metabolites, as well as oxidative stress injury biomarkers) as exposures and OA as an outcome for MR analysis to investigate the potential causal link to provide a theoretical foundation for future research into the complex processes and risk factors of OA. Moreover, Multivariate Mendelian randomization (MVMR) is a recently established method for assessing independent but related exposures at the same time by including genetic variation for each risk factor in the same model (22). Since MVMR has recently been used to disentangle the direct effects of each risk factor on a variety of health outcomes that are not mediated by other associated risk factors, we used it in this study to assess the potential mediating effects of body mass index (BMI), smoking initiation, alcoholic drinks per week, and moderate-to-vigorous physical activity levels.

# 2 Materials and methods

#### 2.1 Study design

For the present study, we performed a two-sample MR to test the associations of absolute circulating levels and corresponding metabolites of antioxidants, as well as oxidative stress injury biomarkers and OA risk. The general design of the current study is illustrated in Figure 1. MR is based on three fundamental assumptions, as genetic instrumental variables should (1) be associated with exposure with the genome-wide significance; (2) not be related to any measured and unmeasured confounders; and (3) not affect the risk of OA through other pathways. All statistics utilized in the present study were derived from publicly available genome-wide association studies (GWAS), and each original study had ethical approval and informed permission. Moreover, our study was conducted based on the MR-STROBE guidance (23).

# 2.2 Selection of genetic instrumental variables

In total, four main diet-derived antioxidants were identified in the present study: vitamin C (ascorbate),  $\beta$ -carotene, lycopene, retinol, and vitamin E ( $\alpha$ - and  $\gamma$ -tocopherol). In the present study, both antioxidants that were measured as real absolute blood levels and their related circulating metabolites that were evaluated as relative plasma or serum concentrations were taken into consideration. For absolute antioxidant levels,  $\alpha$ -tocopherol,  $\beta$ -carotene, lycopene, and retinol were utilized, whereas for antioxidant metabolites,  $\alpha$ -tocopherol, ascorbate,  $\gamma$ -tocopherol, and retinol were included. To identify suitable genetic IVs, a variety of quality control procedures were performed. First, independent single-nucleotide polymorphisms (SNPs) linked with each exposure at genome-wide significance were selected as potential IVs. Second, the linkage disequilibrium (LD) between all SNPs for the same exposure was determined. Finally, to evaluate



the strength of the selected SNPs, the F statistics was calculated using the formula:  $F = R^2 (N-k-1)/[(1-R^2) k]$ , where  $R^2$  is the proportion of variability explained by each SNP, N is the sample size of the GWAS, and k is the number of SNPs. When the F-statistic is more than 10, it implies that IV is a strong instrument (24).

# 2.3 Data sources and SNP selection for absolute circulating antioxidants

For  $\alpha$ -tocopherol, three SNPs were identified in a GWAS with 4,401 participants ( $p < 5 \times 10^{-8}$ , LD < 0.001) (25). Three genetic variants for circulating  $\beta$ -carotene levels were obtained from a GWAS study involving 2,344 subjects in the Nurses' Health Study

 $(p < 5 \times 10^{-8}, \text{LD} < 0.2)$  (26). Five SNPs  $(p < 5 \times 10^{-6}, \text{LD} < 0.001)$  for circulating lycopene level were identified from a published GWAS study involving 441 older Amish adults (27). Two genetic variants associated with circulating retinol were obtained from a GWAS study of 5,006 Caucasian individuals from two cohorts ( $p < 5 \times 10^{-8}, \text{LD} < 0.001$ ) (28).

# 2.4 Data sources and SNP selection for circulating antioxidant metabolites

Genetic variants of circulating antioxidant metabolites were extracted from recent large-scale GWAS ( $p < 1 \times 10^{-5}$ , LD:  $r^2 = 0.001$  and clump distance = 10,000 kb). Eleven instrumental

variables of  $\alpha$ -tocopherol (n = 7,276), 14 instrumental variables of ascorbate (n = 2,063), and 13 instrumental variables of  $\gamma$ -tocopherol (n = 5,822) were obtained from 7,824 adult individuals from two European population studies (29, 30). A total of 26 SNPs associated with retinol were derived from 1,960 subjects of European descent.

### 2.5 Data sources and SNP selection for oxidative stress injury biomarkers

Genetic predictors for oxidative stress injury biomarkers, such as GST, CAT, GPX, SOD, albumin, and total bilirubin, were derived from the most up-to-date GWAS ( $p < 1 \times 10^{-5}$ , LD:  $r^2 = 0.001$  and clump distance = 10,000 kb). Genetic IVs for GST (n = 3,301), CAT (n = 3,301), SOD (n = 3,301), and GPX (n = 3,301) were identified in the INTERVAL study (31). Genetic variants of albumin (n = 115,06) and total bilirubin (n = 342,829) were derived from the UK biobank.

### 2.6 Data sources and SNP selection for OA

As both knee and hip are common sites of OA, summary statistics data on hip, knee, and total OA (hip or knee) were obtained from the publicly available GWAS (32, 33). Zengini et al. performed a GWAS for OA using data across 16.5 million variants from the UK Biobank resource and included 30,727 cases and 297,191 controls. The study by Zengini et al. included self-reported OA and hospital-diagnosed OA patients; the selfreported OA definition includes participants who answered "Yes" to the following question on a touchscreen self-administered questionnaire: "Has a doctor ever told you that you have had any other serious medical conditions or disabilities?;" information on disease code was collected in a subsequent computer-assisted personal interview, and the hospital-diagnosed OA coding in the UK Biobank is based on the ICD-10 code (34). The study by Tachmazidou et al. meta-analyzed the UK Biobank and Arthritis Research UK Osteoarthritis Genetics (arcOGEN) datasets and included 77,052 cases and 378,169 controls. The study by Tachmazidou et al. included the self-reported OA established during an interview with a nurse and the hospital episode statistics ICD10 code for OA in the UK Biobank (34). For the arcOGEN dataset, OA was ascertained based on clinical evidence of disease to a level requiring joint replacement or radiographic evidence of disease (Kellgren–Lawrence grade  $\geq 2$ ) (35, 36).

### 2.7 Multivariate MR analysis

As reported in the study, BMI, alcohol consumption, smoking, and physical activity levels may be risk factors for OA and may influence the effect of dietary sources of oxidants on OA (5, 37). To address this issue, we performed MVMR as a sensitivity analysis to correct for measured confounders, such as BMI, smoking initiation, alcoholic drinks per week, and moderate-to-vigorous physical TABLE 1 Details for selected GWAS of mediators.

Mediators	Sample sizes	PMID
BMI	681,275	30124842
Smoking initiation	607,291	30643251
Alcoholic drinks per week	335,394	30643251
Moderate to vigorous physical activity levels	377,234	29899525

activity levels, which were employed as the potential confounders. For the confounders, we selected the largest published GWAS to date (Table 1).

### 2.8 Statistical analysis

In the univariable MR, to explore the causal associations of genetic variants related to exposures on outcomes, the inversevariance weighting (IVW) method was utilized as the primary analysis for MR. Moreover, MR-Egger, simple mode, weighted median, and weighted mode models were employed as sensitivity analysis methods to test the robustness of the results. If trustworthy instruments are provided by SNPs accounting for at least 50% of the weight, then the weighted median estimate generates valid results as it is the median of the SNP-specific estimates. Even if all genetic variants are invalid, the MR-Egger regression can estimate the underlying causal impact. In addition, the weighted mode approach remains viable even if the other instrumental variables do not meet the MR method's prerequisites for causal inference as long as the majority of IVs have equal causal estimations. Horizontal pleiotropy is defined as some instruments influencing the outcome via paths that bypass the exposure (38). The directionality of pleiotropy can be detected and adjusted using the MR-Egger technique based on the Instrument Strength Independent of Direct Effect (InSIDE) assumption, although it is underpowered (39). Additionally, the MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test was used to detect potential horizontal pleiotropy and reduce the effects of pleiotropy by eliminating outliers (40). The heterogeneity was assessed using Cochran's Q-statistic. The leaveone-out analysis was used to see if any of the significant results were impacted by a specific SNP. Results are expressed as con OA risk for a corresponding unit change in absolute circulating antioxidants levels of a-tocopherol (mg/L in log-transformed scale), lycopene ( $\mu$ g/dL),  $\beta$ -carotene ( $\mu$ g/L in natural log-transformed scale), and retinol (µg/L in natural log-transformed scale), or a 10fold change in circulating antioxidant metabolites concentrations. For analyses with biomarkers level as the exposure, we provide the odds ratios (OR) for OA associated with each standard deviation (SD) increase in levels of biomarkers for oxidative stress damage. For MVMR analysis, the inverse-variance weighted method was employed.

All exposure-specific MR analyses were performed independently in the studies by Tachmazidou et al. (33) and Zengini et al. (32) and then meta-analyzed to obtain pooled estimates for each exposure on OA risk. We used  $I^2$  statistics to

measure heterogeneity between estimates from two studies and the associated *p*-value from Cochran's Q test. When there is no heterogeneity, the fixed-effect model meta-analyses are used to pool instrumental variable estimates across the two outcome databases for each exposure, while random-effect model meta-analyses are employed when there is heterogeneity.

A *p*-value of <0.05 was regarded as suggestive evidence for a possible causal relationship. To account for multiple testing (many exposures), the statistical significance of the MR effect estimates was set at <5% using the Benjamini–Hochberg false discovery rate (FDR). All analyses were carried out in R version 4.3.0 using the packages "TwoSampleMR," "MRPRESSO," and "meta."

### **3** Results

# 3.1 Screening of genetic instrumental variables

The features of genetic instruments identified for dietaryderived antioxidants as absolute levels and metabolites, as well as oxidative stress damage biomarkers, are summarized in Table 2. Supplementary Tables 1–3 provide detailed information on the variants, their associations with antioxidants (beta<sub>gene-exposure</sub>), oxidative stress injury biomarkers, and with OA (beta<sub>gene-outcome</sub>) across databases. The F-statistics for all genetic instruments employed in this study were >10, demonstrating that the IVs were strong instruments, lowering the bias of IV estimates.

# 3.2 Absolute circulating antioxidants and OA

Overall, in the univariable MR analyses using IVW, most genetically determined absolute dietary-derived antioxidant levels were not associated with the risk of OA in both databases, but genetically predicted absolute retinol levels were associated with lower odds hip OA [OR = 0.40, 95% confidence interval (CI) = 0.24-0.68, p = 0.006, FDR-corrected p = 0.042] (Figure 2; Supplementary Tables 5, 6). Pooled odds ratio (OR) for hip OA per unit increase of antioxidants was 0.93 (95% CI = 0.44-1.98, p =0.85, FDR-corrected p = 0.85) for log-transformed  $\alpha$ -tocopherol, 1.06 (95% CI = 0.92–1.21, p = 0.43, FDR-corrected p = 0.62) for natural log-transformed  $\beta$ -carotene, and 1.06 (95% CI = 0.92–1.21, p = 0.38, FDR-corrected p = 0.62) for 1 µg/dl lycopene. Pooled OR for knee OA per unit increase of antioxidants was 0.87 (95% CI =0.59–1.29, p = 0.49, FDR-corrected p = 0.69) for log-transformed  $\alpha$ -tocopherol, 0.99 (95% CI = 0.89–1.10, p = 0.85, FDR-corrected p = 0.86) for natural log-transformed  $\beta$ -carotene, 0.99 (95% CI = 0.89-1.10, p = 0.26, FDR-corrected p = 0.46) for 1 µg/dl lycopene, and 1.16 (95% CI = 0.78-1.75, p = 0.46, FDR-corrected p = 0.69) for natural log-transformed retinol. Pooled OR for total OA per unit increase of anti-oxidants was 0.88 (95% CI = 0.64-1.21, p =0.44, FDR-corrected p = 0.61) for log-transformed  $\alpha$ -tocopherol, 1.01 (95% CI = 0.92–1.11, p = 0.76, FDR-corrected p = 0.76) for natural log-transformed  $\beta$ -carotene, 1.01 (95% CI = 0.92–1.11, p = 0.57, FDR-corrected p = 0.61) for 1 µg/dl lycopene, and 0.81 We obtained similar outcomes using additional MR estimation methods (MR-Egger, weighted median, simple mode, and weighted mode) (Supplementary Tables 4, 5). Basically, no heterogeneity was detected by Cochran's Q test, but there was considerable heterogeneity between lycopene and hip OA from the study by Zengini et al. (Q = 47.25; p = 0.04) (Supplementary Table 6). MR-Egger regression analysis suggested no evidence of directional pleiotropy for the IVs (Supplementary Table 7). The MR-PRESSO test uncovered no evidence of horizontal pleiotropy in the relationships between absolute dietary-derived antioxidant levels and OA (Supplementary Table 8). In addition, the leave-one-out analysis indicated that the most causal association signals were not driven by any single SNP (Supplementary Table 9).

# 3.3 Circulating antioxidant metabolites and OA

In the univariable MR, consistent with the findings from absolute circulating anti-oxidants, most genetically determined absolute dietary-derived antioxidant levels were not associated with the risk of OA in both databases, but genetically predicted circulating retinol levels were associated with higher odds knee OA (OR = 1.02, 95% CI = 1.00-1.05, p = 0.048, FDR-corrected p =0.30) and total OA (OR = 1.02, 95% CI = 1.00–1.04, p = 0.01, FDR-corrected p = 0.07) (Figure 3; Supplementary Tables 10, 11). The combined ORs for hip OA per 10-fold increase in metabolites concentration were 2.03 (95% CI = 0.41-10.06, p = 0.39, FDRcorrected p = 0.62) for  $\alpha$ -tocopherol, 1.03 (95% CI = 0.95–1.11, p = 0.53, FDR-corrected p = 0.62) for ascorbate, 0.93 (95% CI = 0.76–1.15, p = 0.51, FDR-corrected p = 0.62) for  $\gamma$ -tocopherol, and 1.01 (95% CI = 0.98-1.05, p = 0.37, FDR-corrected p = 0.62) for retinol. The combined ORs for knee OA per 10-fold increase in metabolites concentration were 1.21 (95% CI = 0.59-2.50, p =0.60, FDR-corrected p = 0.76) for  $\alpha$ -tocopherol, 0.96 (95% CI = 0.92–1.01, p = 0.13, FDR-corrected p = 0.30) for ascorbate, and 0.88 (95% CI = 0.76–1.03, p = 0.11, FDR-corrected p = 0.30) for γ-tocopherol. The combined ORs for total OA per 10-fold increase in metabolites concentration were 1.32 (95% CI = 0.59-2.94, p =0.49, FDR-corrected p = 0.61) for  $\alpha$ -tocopherol, 0.98 (95% CI = 0.94–1.02, p = 0.36, FDR-corrected p = 0.61) for ascorbate, and 0.92 (95% CI = 0.82–1.04, p = 0.19, FDR-corrected p = 0.61) for  $\gamma$ -tocopherol.

Furthermore, we achieved similar outcomes utilizing additional MR estimation methods (MR-Egger, weighted median, simple mode, and weighted mode) (Supplementary Tables 10, 11). Cochran's Q test revealed no heterogeneity for circulating antioxidant metabolites IVs in three OA types (hip, knee, and total OA) but considerable heterogeneity between  $\gamma$ -tocopherol and total OA from the study by Zengini et al. (Q = 47.25; p = 0.04) (Supplementary Table 12). MR-Egger regression analysis suggested no evidence of directional pleiotropy for the IVs (Supplementary Table 13). MR-PRESSO test uncovered no evidence of horizontal pleiotropy in the relationship between absolute dietary-derived antioxidant levels and OA

Trait	Numbers of SNPs	<i>p</i> -value	Unit	R <sup>2</sup>	F statistic	Participants (Numbers)	PMID		
Absolute circulating antioxidants									
α-tocopherol	3	$5  imes 10^{-8}$	mg/L in log-transformed scale 0.017		86.54	4,014	21729881		
Lycopene	5	$5  imes 10^{-6}$	µg/dL	0.301	189.04	441	26861389		
β-carotene	3	$5 \times 10^{-8}$	μg/L in natural 0.09 231.63 log-transformed scale		2,344	23134893			
Retinol	2	$5 \times 10^{-8}$	μg/L in natural 0.023 117.8 log-transformed scale		5,006	21878437			
Circulating antioxidants metabolites									
α-tocopherol	11	$1 \times 10^{-5}$	log10-transfomed metabolites 0.033 198.61 concentration		7,276	24816252			
γ-tocopherol	13	$1 \times 10^{-5}$	log10-transfomed metabolites concentration	0.15	1027.06	5,822	24816252		
Retinol	24	$1 \times 10^{-5}$	log10-transfomed metabolites concentration	0.048	98.57	1,957	28263315		
Ascorbate	14	$1 \times 10^{-5}$	log10-transfomed metabolites concentration	0.186	470.94	2,063	24816252		
Oxidative stress injury biomarkers levels									
GST	14	$1 \times 10^{-5}$	-	0.013	45.89	3,301	29875488		
CAT	27	$1 \times 10^{-5}$	-	0.007	24.89	3,301	29875488		
SOD	23	$1 \times 10^{-5}$	-	0.008	25.14	3,301	29875488		
GPX	22	$1 \times 10^{-5}$	-	0.011	38.15	3,301	29875488		
Albumin	107	$1 \times 10^{-5}$	-	0.0004	42.20	115,060	-		
Total bilirubin	360	$1 \times 10^{-5}$	-	0.001	418.71	342,829	-		

#### TABLE 2 Details of GWAS studies for diet-derived circulating antioxidants and oxidative stress-related traits.

(Supplementary Table 9). In addition, the leave-one-out analysis indicated that there were SNPs with potential effects on the pooled results, suggesting the need for careful interpretation of the causal association signals (Supplementary Table 14).

### 3.4 Oxidative stress injury biomarkers and OA

Overall, in the univariable MR using IVW, most genetically determined oxidative stress injury biomarkers levels were not associated with the risk of OA in both databases, except each SD higher albumin level was associated with lower odds hip OA (OR = 0.75, 95% CI =  $0.68-0.84, p = 9.88 \times 10-8$ , FDR-corrected p = 1.38 $\times 10^{-6}$ ), lower odds knee OA (OR = 0.82, 95% CI = 0.76-0.89, p =  $3.21 \times 10^{-7}$ , FDR-corrected  $p = 4.49 \times 10^{-6}$ ), and lower odds total OA (OR = 0.80, 95% CI = 0.75–0.86, p = 1.575  $\times$  10-12, FDRcorrected  $p = 2.20 \times 10$ -11) (Figure 4; Supplementary Tables 15, 16). The combined ORs for hip OA in each SD higher oxidative stress injury biomarkers levels were 1.02 (95% CI = 0.98-1.06, p = 0.27, FDR-corrected p = 0.62) for GST, 0.98 (95% CI = 0.95– 1.02, p = 0.33, FDR-corrected p = 0.62) for CAT, 1.01 (95% CI = 0.98-1.05, p = 0.52, FDR-corrected p = 0.62) for SOD, 0.98 (95%) CI = 0.95-1.02, p = 0.30, FDR-corrected p = 0.62) for GPX, and 0.99 (95% CI = 0.93–1.05, p = 0.77, FDR-corrected p = 0.83) for total bilirubin. The combined ORs for knee OA in each SD higher oxidative stress injury biomarkers levels were 1.00 (95% CI = 0.97–1.03, p = 0.85, FDR-corrected p = 0.86) for GST, 0.98 (95% CI = 0.95–1.01, p = 0.18, FDR-corrected p = 0.36) for CAT, 1.00 (95% CI = 0.97–1.04, p = 0.86, FDR-corrected p = 0.86) for SOD, 1.02 (95% CI = 0.99–1.05, p = 0.12, FDR-corrected p = 0.30) for GPX, and 0.96 (95% CI = 0.92–1.01, p = 0.09, FDR-corrected p = 0.30) for total bilirubin. The combined ORs for total OA in each SD higher oxidative stress injury biomarkers levels were 1.01 (95% CI = 0.98–1.03, p = 0.52, FDR-corrected p = 0.47) for CAT, 1.01 (95% CI = 0.98–1.00, p = 0.10, FDR-corrected p = 0.47) for CAT, 1.01 (95% CI = 0.98–1.05, p = 0.52, FDR-corrected p = 0.61) for SOD, 0.98 (95% CI = 0.95–1.02, p = 0.30, FDR-corrected p = 0.61) for GPX, and 0.97 (95% CI = 0.93–1.01, p = 0.14, FDR-corrected p = 0.49) for total bilirubin (Figure 4).

In addition, similar findings were observed when using other MR estimate methods, such as MR-Egger, weighted median, simple mode, and weighted mode (Supplementary Table 16). Cochran's Q test revealed no heterogeneity for circulating antioxidant metabolites IVs in three OA types (hip, knee, and total OA) but considerable heterogeneity for the effects of albumin, CAT, and total bilirubin on OA (Supplementary Table 17). Basically, no directional pleiotropy was detected by MR-Egger regression analysis (all *P*-values for intercept > 0.05), but potential directional pleiotropy between total bilirubin and OA (Supplementary Table 18). The MR-PRESSO test detected some



outliers for the effects of CAT, albumin, and total bilirubin on OA, and the causal effects remained unchanged after the removal of outliers SNPs (Supplementary Table 19). In addition, the leaveone-out analysis indicated that the most causal association signals were not driven by any single SNP, but the potential effect of the total bilirubin on hip OA (from the study by Tachmazidou et al.) may be influenced by some potential SNPs (Supplementary Table 20).

# 3.5 Exploration of the potential confounding factors

In the MVMR analysis, after adjusting for smoking initiation, alcoholic drinks per week, and moderate-tovigorous physical activity levels, the IVW results of MVMR analyses demonstrated that each SD higher albumin level was significantly correlated with the lower risk of hip OA (Table 3). However, the effect of albumin on hip OA was substantially reduced in MVMR analyses incorporating BMI (Table 3). In addition, there are not enough SNPs for MVMR analysis of absolute retinol.

# 4 Discussion

In the present study, we investigated the causal associations between dietary-derived antioxidants/oxidative stress injury biomarkers and OA risk using MR analysis with the large publicly available GWAS datasets. Our findings indicate that the levels of absolute retinol circulating retinol and albumin may be causative factors of OA risk. Moreover, MVMR confirmed that the effect of albumin on hip OA is independent of smoking initiation, alcoholic drinks per week, and moderate-to-vigorous physical activity levels but may be influenced by BMI.

There has been obvious controversy over whether antioxidants reduce the risk of OA. Our study found that there was no causal relationship between vitamin E ( $\alpha$ - and  $\gamma$ -tocopherol),  $\beta$ -Carotene, and lycopene levels and the risk of OA. Previous clinical trials have suggested that oral vitamin E may reduce pain in OA patients (41, 42). In addition, a cross-sectional investigation in a community-based study in Japan found that high serum values of  $\gamma$ -tocopherols were significantly associated with a low risk of radiographic knee OA (43). However, a double-blind, randomized, placebo-controlled study reported that vitamin E was not effective in relieving symptoms of knee OA (44), and a cross-sectional study reported that the vitamin E intake tended to be positively



associated with the tibial plateau bone area, which is a negative effect on the bone and might even increase the OA risk (21). y-Tocopherol is often the most prevalent form of vitamin E in plant seeds, and  $\alpha$ -tocopherol is the predominant form of vitamin E in most human and animal tissues, including blood plasma. In addition, in a prospective cohort study, higher β-Carotene intake was associated with a reduced prevalence of femoral head bone marrow lesions in OA patients (45). In contrast, some crosssectional studies described that carotenoid, including β-Carotene intake, was not significantly associated with cartilage or bone measures or the risk of OA (21, 43). Interestingly, a case-control study reported that the people with the highest levels of trans-betacarotene were more likely to have knee OA (46). A cross-sectional study observed that vitamin C intake was inversely associated with the tibial plateau bone area and with the presence of bone marrow lesions, both of which are important in the pathogenesis of knee OA (21). However, a cohort study observed that there was no association between the dietary vitamin C and the risk of OA (11). A prospective cohort study in Australia reported that higher lycopene intake was associated with a reduced prevalence of femoral head cartilage defects in community-based adults (45). In addition, a case-control study indicated that lower serum lycopene levels were associated with higher pain and physical disability in knee OA patients (47). These disparities might be

attributed to eating habits, subject characteristics, and sample size (48).

Retinol, a form of vitamin A, is a fat-soluble vitamin in the vitamin A family found in food and used as a dietary supplement. Moreover, our pooled results from two databases indicated that absolute retinol level was negatively correlated with hip OA risk, while circulating retinol was positively correlated with knee OA and total OA (hip or knee). A recent MR study reported the inverse causal association between absolute serum retinol levels and hip OA utilizing one GWAS, which is consistent with our pooled results from two databases in our study (49). In addition, a longitudinal cohort study over a 10-year followup period recently described that women with low serum retinol levels develop knee OA at a significantly lower rate among community-dwelling people in Japan (50). Interestingly, a crosssectional investigation in a community-based study reported no associations between serum retinol level and the development of radiographic knee OA in rural Japanese inhabitants (43). Existing research on the role of vitamin A in OA is highly controversial. Some studies reported that the effect of vitamin A on OA was negative (51). There is even evidence that vitamin A metabolite levels are elevated in synovial fluid, serum, and cartilage from patients with OA, and they appear to drive OA development (52, 53).

				В			
	GST and OA		_		CAT and OA		
Study		OR (95%CI)	P value	Study		OR (95%CI)	P valu
Hip OA				Hip OA			
Tachmazidou 2019		1.02 [0.98; 1.06]	0.40	Tachmazidou 2019		0.98 [0.95; 1.02]	0.31
Zengini 2018		1.03 [0.92; 1.15]	0.65	Zengini 2018		1.01 [0.91; 1.12]	0.92
Total (Fixed effect model)	-	1.02 [0.98; 1.06]	0.27	lotal (Fixed effect model)		0.98 [0.95; 1.02]	0.33
Heterogeneity: $I^{\circ} = 0\%$ , $p = 0.87$				Heterogeneity: $I^{-} = 0\%$ , $p = 0.58$			
Knee OA				Knee OA			
Tachmazidou 2019		1.00 [0.97; 1.04]	0.77	Tachmazidou 2019		0.98 [0.95; 1.01]	0.15
Zengini 2018		0.98 [0.90; 1.06]	0.59	Zengini 2018		0.98 [0.89; 1.08]	0.75
Fotal (Fixed effect model) Heterogeneity: $I^2 = 0\%$ , $p = 0.66$		1.00 [0.97; 1.03]	0.85	Total (Fixed effect model) Heterogeneity: $I^2 = 0\%$ , $p = 1.00$		0.98 [0.95; 1.01]	0.18
iotorogonottyr - one p - oroo							
Total OA		1 01 [0 00: 1 04]	0.52	Total OA		0.00 [0.00; 1.01]	0.10
Zangini 2019		0.00 [0.02; 1.04]	0.53	Tachmazidou 2019		0.98 [0.96; 1.01]	0.12
Lengini 2018		1.01 [0.02; 1.06]	0.74	Zengini 2018		0.98 [0.90; 1.07]	0.71
Heterogeneity: $I^2 = 0\%$ , $p = 0.60$		1.01 [0.98; 1.03]	0.52	Heterogeneity: $I^2 = 0\%$ , $p = 1.00$		0.98 [0.96; 1.00]	0.10
				Г		_	
0.8	0.9 1 1.1	1.2		D.8	0.9 1.1	1.2	
Study	SOD and OA	OR (95%CI)	P value	Study	GPX and OA	OR (95%CI)	P value
Hip OA				Hip OA		. ,	
Tachmazidou 2019		1.01 [0.97; 1.05]	0.59	Tachmazidou 2019		0.99 [0.96; 1.03]	0.61
Zengini 2018		1.03 [0.92; 1.15]	0.61	Zengini 2018		0.93 [0.84; 1.02]	0.16
Total (Fixed effect model)	-	1.01 [0.98; 1.05]	0.52	Total (Fixed effect model)	-	0.98 [0.95; 1.02]	0.30
Heterogeneity: $I^2 = 0\%$ , $p = 0.75$				Heterogeneity: $I^2 = 30\%$ , $p = 0.23$			
Knee OA				Knee OA			
Tachmazidou 2019		1.00 [0.97; 1.04]	0.79	Tachmazidou 2019		1.02 [0.99; 1.05]	0.29
Zengini 2018		1.02 [0.94; 1.11]	0.61	Zengini 2018		1.03 [0.96; 1.10]	0.44
<b>Total (Fixed effect model)</b> Heterogeneity: $I^2 = 0\%$ , $p = 0.67$	-	1.00 [0.97; 1.04]	0.86	Total (Fixed effect model) Heterogeneity: $I^2 = 0\%$ , $p = 0.80$	-	1.02 [0.99; 1.05]	0.12
Total OA		1 01 50 00 1 0 12	0.00	Total OA	L	1 0 1 10 00 1 003	
Tacrimazidou 2019		1.01 [0.98; 1.04]	0.39	Tachmazidou 2019	- <b>T</b>	1.01 [0.99; 1.03]	0.48
Zengini 2018 Total (Fixed effect model)		1.04 [0.97, 1.12]	0.25	Zengini 2018		0.99 [0.94; 1.05]	0.77
Heterogeneity: $I^2 = 0\%$ , $p = 0.46$		1.01 [0.33, 1.04]	0.51	Heterogeneity: $I^2 = 0\%$ , $p = 0.50$		1.01 [0.99, 1.03]	0.42
				F			
0.8	0.9 1 1.1	1.2		• 0.0		1.2	
Study	Albumin and OA	OR (95%CI)	P value	Study	Total bilirubin and	OR (95%CI)	P valu
Hip OA				Hip OA			
Tachmazidou 2019		0.77 [0.68; 0.87]	3.14E-06	Tachmazidou 2019	-	1.00 [0.93; 1.06]	0.91
Zengini 2018 -		0.69 [0.55; 0.87]	1.76E-03	Zengini 2018		0.95 [0.82; 1.09]	0.43
Total (Fixed effect model)		0.75 [0.68; 0.84]	9.88E-08	Total (Fixed effect model)	-	0.99 [0.93; 1.05]	] 0.77
Heterogeneity: $I = 0\%$ , $p = 0.40$				Heterogeneity: $I^{-} = 0\%$ , $p = 0.52$			
Knee OA	-	0.92 [0.76, 0.00]	1.055.05	Knee OA		0.07 [0.00. 4.00]	0.04
Zencini 2018		0.03 [0.76; 0.90]	5.37E-02	Zengini 2018		0.97 [0.92; 1.02]	0.24
Total (Fixed effect model)	-	0.82 [0.76 • 0.84]	3 21 E-03	Total (Fixed effect model)		0.92 [0.03, 1.03]	1 0.14
Heterogeneity: $I^2 = 0\%$ , $p = 0.61$		[0.1.0, 0.00]		Heterogeneity: $I^2 = 0\%$ , $p = 0.39$			, 0.50
Total OA				Total OA			
Tachmazidou 2019		0.81 [0.76: 0.87]	2.01E-08	Tachmazidou 2019		0.98 [0.93: 1.02]	0.32
Zengini 2018		0.77 [0.67: 0.89]	2.54E-04	Zengini 2018		0.93 [0.85: 1.02]	0.14
Total (Fixed effect model)	-	0.80 [0.75; 0.85]	1.57E-12	Total (Fixed effect model)	-	0.97 [0.93; 1.01]	0.14
Heterogeneity: $I^2 = 0\%$ , $p = 0.53$				Heterogeneity: $I^2 = 1\%$ , $p = 0.32$			
Г	1						
0.5	0.0 1	1 05		0	76 1	1 05	
	<b>iip OA</b> Iachmazidou 2019 Zengini 2018 <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.87$ <b>Knee OA</b> <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.66$ <b>Fotal OA</b> <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.60$ <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.60$ <b>Study</b> <b>Hip OA</b> Tachmazidou 2019 Zengini 2018 <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.60$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.67$ <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.67$ <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.46$ <b>Study</b> <b>Hip OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.46$ <b>Study</b> <b>Hip OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.40$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.53$	<b>iip OA</b> Iachmazidou 2019 Zengini 2018 <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.87$ <b>Knee OA</b> Iachmazidou 2019 Zengini 2018 <b>Fotal (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.60$ <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.60$ <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.75$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.67$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.67$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.67$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.46$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.46$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.40$ <b>Knee OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.61$ <b>Total OA</b> Tachmazidou 2019 Zengini 2018 <b>Total (Fixed effect model)</b> Heterogeneity: $l^2 = 0\%$ , $p = 0.53$	tip OA fachmazidou 2019 Zengini 2018 1.02 [0.96; 1.06] 1.03 [0.92; 1.15]   Total (Fixed effect model) +tetrogeneity: $f^2 = 0\%$ , $p = 0.67$ 1.00 [0.97; 1.04] 0.98 [0.90; 1.06]   Total (Fixed effect model) +tetrogeneity: $f^2 = 0\%$ , $p = 0.66$ 1.01 [0.99; 1.04] 0.99 [0.92; 1.06]   Total (Fixed effect model) +tetrogeneity: $f^2 = 0\%$ , $p = 0.60$ 0.8 0.9 1 1.1 1.2   Study SOD and OA 0.8 0.9 1 1.1 1.2 0.8 (9.9; 1.06]   Tachmazidou 2019 Zengini 2018 1.01 [0.98; 1.03]   Total (Fixed effect model) +tetrogeneity: $f^2 = 0\%$ , $p = 0.75$ 1.01 [0.97; 1.04]   Hip OA Tachmazidou 2019 Zengini 2018 1.01 [0.98; 1.05]   Total (Fixed effect model) Heterogeneity: $f^2 = 0\%$ , $p = 0.67$ 1.01 [0.98; 1.04]   Hip OA Tachmazidou 2019 Zengini 2018 1.01 [0.98; 1.04]   Total (Fixed effect model) Heterogeneity: $f^2 = 0\%$ , $p = 0.67$ 1.01 [0.98; 1.04]   Heterogeneity: $f^2 = 0\%$ , $p = 0.67$ 1.01 [0.98; 1.04]   Total (Fixed effect model) Heterogeneity: $f^2 = 0\%$ , $p = 0.46$ 0.8 0.9 1 1.1 1.2   Study OR (95%CI) 0.77 [0.68; 0.87]   Not [0.75; 0.85] 0.77 [0.66; 0.87] 0.77 [0.66; 0.87]   Total (Fixed effect model) Heterogeneity: $f^2 = 0\%$ , $p = 0.61$ 0.83 [0.76; 0.90] 0.77 [0.66; 0.87]   Total (Fixed effect model)	tip OA fachmazidou 2019 Zengini 2018 1.02 [0.98; 1.06] 0.40   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.87$ 0.85 0.65   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.67$ 1.00 [0.97; 1.04] 0.77   Cachmazidou 2019 Zengini 2018 1.00 [0.97; 1.04] 0.59   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.66$ 1.01 [0.99; 1.04] 0.53   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.60$ 1.01 [0.97; 1.04] 0.52   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.60$ 1.01 [0.97; 1.04] 0.52   Total (Fixed effect model) telerogeneity: $F^* = 0\%$ , $p = 0.67$ 1.01 [0.97; 1.04] 0.52   Total (Fixed effect model) Heterogeneity: $F^* = 0\%$ , $p = 0.67$ 1.00 [0.97; 1.04] 0.52   Total (Fixed effect model) Heterogeneity: $F^* = 0\%$ , $p = 0.67$ 1.00 [0.97; 1.04] 0.86   Total (Fixed effect model) Heterogeneity: $F^* = 0\%$ , $p = 0.67$ 1.01 [0.98; 1.04] 0.39   Total (Fixed effect model) Heterogeneity: $F^* = 0\%$ , $p = 0.67$ 0.77 [0.68; 0.87] 3.14E-06   0.8 0.9 1 1.1 1.2   Study Albumin and OA OR (95%cl) P value   Total (Fixed effect model) Het	Hip OA Bachmarkou 2019 Zengini 2018 Hip ÓA Tachmarkou 2019 Zengini 2018 Hip ÓA Tachmarkou 2019 Zengini 2018   Total (Fixed effect model) Heterogeneity: $F = 0\%$ , $p = 0.87$ 1.02 [0.98; 1.06] 0.27 Hip ÓA   Tachmarkou 2019 1.00 [0.97; 1.04] 0.77 1.03 [0.92; 1.16] 0.85   Total (Fixed effect model) 1.00 [0.97; 1.03] 0.53 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.99; 1.04] 0.53 Total (Fixed effect model)   Tachmarkou 2019 0.9 1 1.01 [0.99; 1.04] 0.52   Total (Fixed effect model) 1.01 [0.99; 1.04] 0.53 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.99; 1.04] 0.53 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.99; 1.04] 0.53 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.97; 1.04] 0.74 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.97; 1.04] 0.74 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.97; 1.04] 0.59 Total (Fixed effect model)   Tachmarkou 2019 1.01 [0.97; 1.04] 0.79 Tachmarkou 2019 Total (Fixed effect model)   Tachmarkou 2019 T	tip OA Aragin 2019 Aragin 2019 Cranit (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Cral (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Cral (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Cral (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Cral (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Cral (Fixed effect model) Haterogenety, $F = 0\%, p = 0.57$ Aragin 2019 Aragin	tip OA Enromatobus 2019 Enromatobus 2019 En

Causal associations between oxidative stress injury biomarkers and OA. The effect of (A) GST, (B) CAT, (C) SOD, (D) GPX, (E) albumin, and (F) total bilirubin absolute retinol on OA risk.

TABLE 3 Causal effect of albumin on hip OA in multivariable Mendelian randomization analyses.

Mediators adjusted	Effect of albumin or	n Hip OA (33)	Effect of albumin on Hip OA ( 😳 )		
	Effect estimate (IVW): OR (95% CI)	p	Effect estimate (IVW): OR (95% CI)	p	
BMI	0.93 (0.79, 1.09)	0.09	0.88 (0.60, 1.3)	0.63	
Smoking initiation	0.78 (0.70, 0.87)	$1.27 \times 10^{-5}$	0.76 (0.58, 0.98)	0.04	
Alcoholic drinks per week	0.78 (0.69, 0.87)	$1.91  imes 10^{-5}$	0.68 (0.54, 0.86)	0.001	
Moderate to vigorous physical activity levels	0.80 (0.72, 0.89)	$2.55 \times 10^{-5}$	0.74 (0.58, 0.95)	0.02	

Enzymatic antioxidants such as GST, CAT, SOD, and GPX can limit peroxide generation and eliminate free radicals (54). Several studies have reported OA disease models with lower GSH, GPX, CAT, and SOD levels (14-16), as well as higher total bilirubin levels (17). Interestingly, other studies observed no significant difference in the GSH level, as well as the activity of SOD and GPX between OA patients and control people was insignificantly lower than in healthy people (55, 56). Non-enzymatic antioxidants, including albumin and bilirubin, which break the free radical chain reaction interacting with ROS, also play a key role in the antioxidant system (54). Approximately 5% human serum albumin has been reported to reduce pain and effectively treat OA in patients by increasing anti-inflammatory prostaglandins, promoting inflammation and healing as well as cartilage regeneration (57). Our results support the finding and indicate that a high albumin level was associated with a lower risk of OA. Yet, some studies reported no significant differences in plasma and synovial fluid albumin levels between OA patients and healthy people, which may be limited by the small sample sizes (58).

The present study has several strengths. First, MR uses genetic variation as a proxy for environmental exposure to determine the causal relationship between exposure and disease outcome. Genetic differences are assumed to be randomly assigned before birth, are highly independent of environmental variables such as dietary patterns and lifestyle, and are established before the onset of disease. Therefore, MR analyses using genetic variation as an instrumental variable for exposure may reduce the bias of causal reversals and confounders common in observational studies. Second, we further restricted the inclusion of populations of European ancestry to minimize population stratification. In addition, we conducted a meta-analysis of two large databases, and the results from these two databases were largely consistent with weak evidence of heterogeneity, supporting the robustness of our findings. Thus, despite the limited number of robust genetic instruments, the precision of the final MR estimates and the reliability of the results were significantly improved.

However, some limitations concerning the interpretation of the results should also be considered. First, we were unable to test for a non-linear causal link between antioxidant levels and OA risk since the published data we used were summary-level statistics. Second, sensitivity analysis could not be performed due to the limited number of SNPs for the absolute retinol instrumental variable, and a large GWAS of antioxidants will be required in future to increase the instrument's variable strength. Third, the lack of demographic data, such as gender and ethnicity, and other relevant characteristics in the original study prevented additional subgroup analyses. Finally, we were unable to explore the association between antioxidant use and risk of OA in nutritionally deficient populations that may be more interested in supplementing with antioxidants or testing the effects of antioxidants in combination with other treatments. Furthermore, due to the availability of data, this study focused on populations of European origin, and further validation of associations in other populations is needed.

Evidence from the present study supports the beneficial role of absolute circulating retinol levels and albumin in OA. Dietary retinol and albumin supplementation may be a useful strategy for the primary prevention of OA in high-risk individuals.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

## Author contributions

YT, WZ, and TZ mainly designed the study. YT performed analysis, verified data, and wrote the manuscript. XX, SZ, and WK analyzed data, performed the literature search, and wrote the manuscript. WZ and TZ supervised the manuscript. All authors have read, provided critical feedback on intellectual content, and approved the final manuscript.

## Funding

This study was supported by the National Key R&D Program of China (No. 2018YFC2001800 to TZ), the Natural Science Foundation of Sichuan Province (No. 2023NSFSC0512 to TZ), the National Natural Science Foundation of China (No. 82301371 to YT), the Post-Doctor Research Project, West China Hospital, Sichuan University (No. 2021HXBH059 to YT), the Fundamental Research Funds for the Central Universities (No. 2023SCU12075 to YT), and the Science and Technology Plan Project of Sichuan Province (No. 2023NSFSC1780 to YT).

# Acknowledgments

The authors thank the consortiums for sharing these data.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2023. 1233086/full#supplementary-material

## References

1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. (2019) 393:1745– 59. doi: 10.1016/S0140-6736(19)30417-9

2. Colletti A, Cicero AFG. Nutraceutical approach to chronic osteoarthritis: from molecular research to clinical evidence. *Int J Mol Sci.* (2021) 22:12920. doi: 10.3390/ijms222312920

3. Zhang Y, Liu T, Yang H, He F, Zhu X. Melatonin: a novel candidate for the treatment of osteoarthritis. *Ageing Res Rev.* (2022) 78:101635. doi: 10.1016/j.arr.2022.101635

4. Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. *Free Radic Biol Med.* (2019) 132:73–82. doi: 10.1016/j.freeradbiomed.2018.08.038

5. Ansari MY, Ahmad N, Haqqi TM. Oxidative stress and inflammation in osteoarthritis pathogenesis: role of polyphenols. *Biomed Pharmacother*. (2020) 129:110452. doi: 10.1016/j.biopha.2020.110452

6. Tudorachi NB, Totu EE, Fifere A, Ardeleanu V, Mocanu V, Mircea C, et al. The Implication of reactive oxygen species and antioxidants in knee osteoarthritis. *Antioxidants.* (2021) 10:985. doi: 10.3390/antiox10060985

7. Grover AK, Samson SE. Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality. *Nutr J.* (2016) 15:1. doi: 10.1186/s12937-015-0115-z

8. Messina OD, Vidal Wilman M, Vidal Neira LF. Nutrition, osteoarthritis and cartilage metabolism. *Aging Clin Exp Res.* (2019) 31:807–13. doi: 10.1007/s40520-019-01191-w

9. Dunlap B, Patterson GT, Kumar S, Vyavahare S, Mishra S, Isales C, et al. Vitamin C supplementation for the treatment of osteoarthritis: perspectives on the past, present, and future. *Ther Adv Chronic Dis.* (2021) 12:20406223211047026. doi: 10.1177/20406223211047026

10. Rosenbaum CC, O'Mathúna DP, Chavez M, Shields K. Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. *Altern Ther Health Med.* (2010) 16:32–40. doi: 10.1136/aim.2010.002451

11. Veen L, Hantikainen E, Bellocco R, Ye W, Serafini M, Ponzano M, et al. Dietary antioxidants, non-enzymatic antioxidant capacity and the risk of osteoarthritis in the swedish national march cohort. *Eur J Nutr.* (2021) 60:169–78. doi: 10.1007/s00394-020-02239-8

12. O'Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. *Best Pract Res Clin Rheumatol.* (2018) 32:312–26. doi: 10.1016/j.berh.2018.10.007

13. Liu L, Luo P, Yang M, Wang J, Hou W, Xu P. The role of oxidative stress in the development of knee osteoarthritis: a comprehensive research review. *Front Mol Biosci.* (2022) 9:1001212. doi: 10.3389/fmolb.2022.1001212

14. Marchev AS, Dimitrova PA, Burns AJ, Kostov RV, Dinkova-Kostova AT, Georgiev MI. Oxidative stress and chronic inflammation in osteoarthritis: can Nrf2 counteract these partners in crime? *Ann N Y Acad Sci.* (2017) 1401:114–35. doi: 10.1111/nyas.13407

15. Zhao Q, Tang Y, Zhang L, Sun N, Liu Q, Zhang R. Biological functions of selenoprotein glutathione peroxidases (Gpxs) and their expression in osteoarthritis. *J Inflamm Res.* (2023) 16:183–96. doi: 10.2147/JIR.S388934

16. Jokić A, Sremcević N, Karagülle Z, Pekmezović T, Davidović V. Oxidative stress, hemoglobin content, superoxide dismutase and catalase activity influenced by sulphur baths and mud packs in patients with osteoarthritis. *Vojnosanit Pregl.* (2010) 67:573–8. doi: 10.2298/VSP1007573J

17. Costa-Cavalcanti RG, de Sá-Caputo DDC, Moreira-Marconi E, Küter CR, Brandão-Sobrinho-Neto S, Paineiras-Domingos LL, et al. Effect of auriculotherapy on the plasma concentration of biomarkers in individuals with knee osteoarthritis. *J Acupunct Meridian Stud.* (2018) 11:145–52. doi: 10.1016/j.jams.2018.05.005

18. Krachler M, Domej W. Clinical laboratory parameters in osteoarthritic kneejoint effusions correlated to trace element concentrations. *Biol Trace Elem Res.* (2001) 79:139–48. doi: 10.1385/BTER:79:2:139

19. Shabestari M, Shabestari YR, Landin MA, Pepaj M, Cleland TP, Reseland JE, et al. Altered protein levels in bone marrow lesions of hip osteoarthritis: analysis by proteomics and multiplex immunoassays. *Int J Rheum Dis.* (2020) 23:788–99. doi: 10.1111/1756-185X.13843

20. Nasui BA, Talaba P, Nasui GA, Sirbu DM, Borda IM, Pop AL, et al. The influence of diet and physical activity on oxidative stress in Romanian females with osteoarthritis. *Nutrients.* (2022) 14:4159. doi: 10.3390/nu14194159

21. Wang Y, Hodge AM, Wluka AE, English DR, Giles GG, O'Sullivan R, et al. Effect of antioxidants on knee cartilage and bone in healthy, middle-aged subjects: a cross-sectional study. *Arthritis Res Ther.* (2007) 9:R66. doi: 10.1186/ar2225

22. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol.* (2015) 181:251-60. doi: 10.1093/aje/kwu283

23. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the strobe-mr statement. *JAMA*. (2021) 326:1614–21. doi: 10.1001/jama.2021.18236

24. Miao R, Li J, Meng C, Li Y, Tang H, Wang J, et al. Diet-derived circulating antioxidants and risk of stroke: a Mendelian randomization study. Oxid Med Cell Longev. (2022) 2022:6457318. doi: 10.1155/2022/6457318

25. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, et al. Genomewide association study identifies common variants associated with circulating vitamin E levels. *Hum Mol Genet.* (2011) 20:3876–83. doi: 10.1093/hmg/ddr296

26. Hendrickson SJ, Hazra A, Chen C, Eliassen AH, Kraft P, Rosner BA, et al. B-Carotene 15,15/-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. *Am J Clin Nutr.* (2012) 96:1379–89. doi: 10.3945/ajcn.112.034934

27. D'Adamo CR, D'Urso A, Ryan KA, Yerges-Armstrong LM, Semba RD, Steinle NI, et al. A common variant in the Setd7 gene predicts serum lycopene concentrations. *Nutrients.* (2016) 8:82. doi: 10.3390/nu8020082

28. Mondul AM, Yu K, Wheeler W, Zhang H, Weinstein SJ, Major JM, et al. Genome-wide association study of circulating retinol levels. *Hum Mol Genet.* (2011) 20:4724–31. doi: 10.1093/hmg/ddr387

29. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. *Nat Genet.* (2014) 46:543–50. doi: 10.1038/ng.2982

30. Long T, Hicks M, Yu HC, Biggs WH, Kirkness EF, Menni C, et al. Wholegenome sequencing identifies common-to-rare variants associated with human blood metabolites. *Nat Genet.* (2017) 49:568–78. doi: 10.1038/ng.3809

31. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. *Nature*. (2018) 558:73–9. doi: 10.1038/s41586-018-0175-2

32. Zengini E, Hatzikotoulas K, Tachmazidou I, Steinberg J, Hartwig FP, Southam L, et al. Genome-wide analyses using Uk biobank data provide insights into the genetic architecture of osteoarthritis. *Nat Genet.* (2018) 50:549–58. doi: 10.1038/s41588-018-0079-y

33. Tachmazidou I, Hatzikotoulas K, Southam L, Esparza-Gordillo J, Haberland V, Zheng J, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of Uk biobank data. *Nat Genet.* (2019) 51:230–6. doi: 10.1038/s41588-018-0327-1

34. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. Uk biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* (2015) 12:e1001779. doi: 10.1371/journal.pmed.1001779

35. Panoutsopoulou K, Southam L, Elliott KS, Wrayner N, Zhai G, Beazley C, et al. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcogen study. *Ann Rheum Dis.* (2011) 70:864–7.

36. Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, et al. Identification of new susceptibility loci for osteoarthritis (Arcogen): a genome-wide association study. *Lancet.* (2012) 380:815–23. doi: 10.1016/S0140-6736(12)60681-3

37. Gay C, Chabaud A, Guilley E, Coudeyre E. Educating patients about the benefits of physical activity and exercise for their hip and knee osteoarthritis. systematic literature review. *Ann Phys Rehabil Med.* (2016) 59:174-83. doi: 10.1016/j.rehab.2016.02.005

38. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet.* (2014) 23:R89-98. doi: 10.1093/hmg/ddu328

39. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. *Int J Epidemiol.* (2015) 44:512–25. doi: 10.1093/ije/dyv080

40. Tang Y, Liu W, Kong W, Zhang S, Zhu T. Multisite chronic pain and the risk of autoimmune diseases: a Mendelian randomization study. *Front Immunol.* (2023) 14:1077088. doi: 10.3389/fimmu.2023.1077088

41. Dehghan M. Comparative effectiveness of B and E vitamins with diclofenac in reducing pain due to osteoarthritis of the knee. *Med Arch.* (2015) 69:103-6. doi: 10.5455/medarh.2015.69.103-106

42. Haflah NH, Jaarin K, Abdullah S, Omar M. Palm vitamin E and glucosamine sulphate in the treatment of osteoarthritis of the knee. *Saudi Med J.* (2009) 30:1432–8. doi: 10.1136/jech.44.3.249

43. Seki T, Hasegawa Y, Yamaguchi J, Kanoh T, Ishiguro N, Tsuboi M, et al. Association of serum carotenoids, retinol, and Tocopherols with radiographic knee osteoarthritis: possible risk factors in rural Japanese inhabitants. *J Orthop Sci.* (2010) 15:477-84. doi: 10.1007/s00776-010-1491-z

44. Brand C, Snaddon J, Bailey M, Cicuttini F. Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study. *Ann Rheum Dis.* (2001) 60:946–9. doi: 10.1136/ard.60.10.946

45. Wang Y, Smith S, Teichtahl AJ, Hodge AM, Wluka AE, Giles GG, et al. Association between dietary intake of antioxidants and prevalence of femoral head cartilage defects and bone marrow lesions in community-based adults. *J Rheumatol.* (2016) 43:1885–90. doi: 10.3899/jrheum.160325

46. De Roos AJ, Arab L, Renner JB, Craft N, Luta G, Helmick CG, et al. Serum carotenoids and radiographic knee osteoarthritis: the Johnston county osteoarthritis project. *Public Health Nutr.* (2001) 4:935–42. doi: 10.1079/PHN2001132

47. Eftekharsadat B, Aghamohammadi D, Dolatkhah N, Hashemian M, Salami H. Lower serum levels of alpha tocopherol and lycopene are associated with higher pain and physical disability in subjects with primary knee osteoarthritis: a case-control study. *Int J Vitam Nutr Res.* (2021) 91:304–14. doi: 10.1024/0300-9831/a000635

48. Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol. (2005) 17:141-6. doi: 10.1097/01.cco.0000152664.87204.3c

49. Qu Z, Yang F, Hong J, Wang W, Li S, Jiang G, et al. Causal relationship of serum nutritional factors with osteoarthritis: a Mendelian randomization study. *Rheumatology.* (2021) 60:2383–90. doi: 10.1093/rheumatology/keaa622

50. Takemoto G, Seki T, Takegami Y, Osawa Y, Makida K, Ochiai S, et al. The development of knee osteoarthritis and serum carotenoid levels among community-dwelling people in Japan. *Mod Rheumatol.* (2022) 32:205–12. doi: 10.1080/14397595.2021.1900030

51. Canter PH, Wider B, Ernst E. The antioxidant vitamins a, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. *Rheumatology*. (2007) 46:1223–33. doi: 10.1093/rheumatology/kem116

52. Davies MR, Ribeiro LR, Downey-Jones M, Needham MR, Oakley C, Wardale J. Ligands for retinoic acid receptors are elevated in osteoarthritis and may contribute to pathologic processes in the osteoarthritic joint. *Arthritis Rheum.* (2009) 60:1722–32. doi: 10.1002/art.24550

53. Zheng XY, Liang J, Li YS, Tu M. Role of fat-soluble vitamins in osteoarthritis management. *J Clin Rheumatol.* (2018) 24:132– 7. doi: 10.1097/RHU.00000000000587

54. Lu Z, Pu C, Zhang Y, Sun Y, Liao Y, Kang Z, et al. Oxidative stress and psychiatric disorders: evidence from the bidirectional Mendelian randomization study. *Antioxidants.* (2022) 11:1386. doi: 10.3390/antiox11071386

55. Olszewska-Słonina DM, Matewski D, Drewa G, Wozniak A, Czajkowski R, Rajewski P, et al. Oxidative equilibrium in the prophylaxis of degenerative joint changes: an analysis of pre- and postoperative activity of antioxidant enzymes in patients with hip and knee osteoarthritis. *Med Sci Monit.* (2010) 16:Cr238–45. doi: 10.1016/j.mehy.2009.07.026

56. Sutipornpalangkul W, Morales NP, Charoencholvanich K, Harnroongroj T. Lipid peroxidation, glutathione, vitamin E, and antioxidant enzymes in synovial fluid from patients with osteoarthritis. *Int J Rheum Dis.* (2009) 12:324–8. doi: 10.1111/j.1756-185X.2009.01430.x

57. Bar-Or D, Thomas GW, Rael LT, Gersch ED, Rubinstein P, Brody E. Low molecular weight fraction of commercial human serum albumin induces morphologic and transcriptional changes of bone marrow-derived mesenchymal stem cells. *Stem Cells Transl Med.* (2015) 4:945–55. doi: 10.5966/sctm. 2014-0293

58. Yazar M, Sarban S, Kocyigit A, Isikan UE. Synovial fluid and plasma selenium, copper, zinc, and iron concentrations in patients with rheumatoid arthritis and osteoarthritis. *Biol Trace Elem Res.* (2005) 106:123–32. doi: 10.1385/BTER:106:2:123